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Abstract
Severe liver disease caused by chronic hepatitis C virus is the major indication for liver transplantation. Despite recent advances in antiviral therapy, drug toxicity and unwa nted side-effects render effective treatment in liver-transplanted patients a challenging task.
Virus-specific therapeutic antibodies are generally safe and well-tolerated, but their potential in preventing and treating HCV infection has not yet been realized due to a variety of issues, not least high production costs and virus variability. Heavy-chain antibodies (HCAbs) or nanobodies, produced by camelids, represent an exciting antiviral approachthey can target novel highly conserved epitopes that are inaccessible to normal antibodies and they are also easy to manipulate and produce. We isolated four distinct nanobodies from a phage-display library generated from an alpaca immunized with Hepatitis C virus E2
glycoprotein. One of them, nanobody D03, recognized a novel epitope overlapping with the epitopes of several broadly neutralizing human monoclonal antibodies. Its crystal structure revealed a long CDR3 folding over part of the framework that -in conventional antibodies -forms the interface between heavy and light chain. D03 neutralized a panel of retroviral particles pseudotyped with HCV glycoproteins from six genotypes and authentic cellculture derived particles by interfering with E2-CD81 interaction. In contrast to some of the most broadly neutralizing human anti-E2 mAbs, D03 efficiently inhibited HCV cell-to-cell transmission. Conclusion: This is the first description of a potent and broadly neutralizing HCV-specific nanobody representing a significant advance that will lead to future development of novel entry inhibitors for the treatment and prevention of HCV infection and help our understanding of HCV cell-to-cell transmission.
An estimated 180 million people worldwide are infected with the hepatitis C virus (HCV).
Chronic infection is frequent and often leads to progressive liver disease with chronic HCV infection being the leading indication for liver transplantation (1) . HCV exhibits significant genetic diversity, and at least six major genotypes, which differ by up to 30% in their nucleotide sequence, have been identified (2) . Therapeutic administration of anti-HCV neutralizing antibodies may contribute to future combination therapies with protease and/or polymerase inhibitors. The HCV glycoproteins E1 and E2 are the major target for neutralizing antibodies and immunization studies have generated broadly reactive antibody responses (7) . Neutralizing human monoclonal antibodies specific for HCV E2 have been shown to protect against heterologous virus challenge in a human liver-chimeric mouse model (8) and in chimpanzees (9) . More recently a neutralizing human monoclonal antibody specific for HCV E2 was reported to delay viral rebound in patients following liver transplantation (10) . Viral clearance during acute infection is associated with the presence of high titer neutralizing antibodies (11) (12) (13) .
However, reports that HCV can evade neutralizing antibodies by transmitting via cell-to-cell contacts raised concerns on the efficacy of antibodies targeting the viral glycoproteins to limit viral transmission (14) (15) (16) .
In members of the family Camelidae a large proportion of the humoral immune response is comprised of homodimeric IgG devoid of light chains (~80 kD) (17) . These "heavy chain" antibodies also lack the C H 1 region and their variable region is referred to as VHH or nanobody. Recombinant nanobodies (~14 kD) are intact antigen-binding domains and exhibit a broad antigen-binding repertoire. They have unique characteristics, including an extended CDR3 loop that can adopt a protruding conformation allowing interaction with concave epitopes that are occluded for conventional antibodies (18) . To stabilize the enlarged CDRs, nanobodies often possess an additional disulfide bond between CDR1 and CDR3 in dromedaries, and CDR2 and CDR3 in llamas (19) . Nanobodies have been raised to numerous viruses (reviewed in (20) ) and in spite of being monovalent they frequently exhibit biological activities comparable to conventional bivalent antibody molecules (21) .
As such, nanobodies are a promising tool for the targeted immunotherapy of viral infections.
Here we report the isolation and characterization of four anti-HCV alpaca nanobodies raised by immunizing an alpaca with recombinant hepatitis C virus E2 glycoprotein. One of these nanobodies neutralized HCVpp representing diverse genotypes, authentic HCVcc virions, and uniquely inhibited HCV cell-to-cell transmission. This provides the first evidence of nanobodies as potential candidates for immunotherapeutic administration in chronic hepatitis C.
Experimental procedures

HCVpp and HCVcc neutralization assays
HCVpp and 100 focus-forming units of JFH-1, respectively, were mixed with serum, nanobody, or monoclonal antibody for one hour before adding to Huh7.5 cells. Further experimental details are provided in SI Materials and Methods.
Nanobody crystallization, data collection and structure determination
Crystals of the nanobody D03 were grown at 293 K using the sitting-drop vapor-diffusion method in drops containing 1.2 μL protein (~20 mg/ml in 10 mM TRIS pH 8.0, 150 mM NaCl) mixed with 1.2 μL reservoir solution containing 2005 mM LiSO4. Diffraction quality rod-like crystals belonging to spacegroup P6 5 appeared after weeks. Data collection, processing and structure solution are described in more detail in SI Materials and Methods.
Inhibition of HCV cell-to-cell transmission
Cell-to cell transmission was analysed as described before (22 
Results
Nanobodies neutralize HCV infectivity.
We used a phage-display library isolated from an alpaca immunized with HCV E2 to identify four nanobodies specifically recognizing E2 ( Figure S1 ). The nanobodies were expressed in E.coli and antigen specificity demonstrated by pull-down and immunofluorescence assay ( Figure S2 ). All four nanobodies were assessed for their ability to inhibit HCVpp and HCVcc infection. Determination of autologous neutralization of HCVpp bearing glycoproteins of the immunogen HCV isolate UKN2B2.8 revealed that D03 neutralized virus infection in a dose-dependent manner (>95% at 20µg mL -1 ), while C09 possessed some neutralizing activity, and B11 and D04 had no effect on HCVpp infectivity ( Figure S3d ). Subsequent analysis using JFH-1 HCVcc revealed that D03 had the strongest neutralizing effect, while C09 had a minor inhibitory effect ( Figure 1a ). B11
and D04 did not show any neutralizing activity. Together these data demonstrated that D03
neutralizes the infectivity of HCVpp and HCVcc expressing glycoproteins of HCV genotype 2.
To assess the breadth of neutralizing activity, all four nanobodies were screened at a single concentration for their inhibitory effect on entry of pseudoparticles bearing a well- and UKN2B1.1 (genotype 2b), were more easily neutralized by D03 than by mAb 1:7 (used as positive control (24)). However, other strains such as UKN3A13.6 (genotype 3a) and UKN5.15.7 (genotype 5) were more refractory to neutralization by D03 and required significantly more nanobody to achieve 50% inhibition. These results indicated that the epitope recognized by D03 is conserved across genetically diverse isolates, but presentation of the epitope at the virion surface may differ between strains.
Crystal structure of D03.
To gain insight into the conformation of its potential antigen binding determinants we crystallized D03 and determined its crystal structure to 1.8Å resolution; details and statistics of the data collection, processing and refinement are given in Table S1 . As We defined D03 contact residues in E2 by binding analysis of D03 to a panel of HCV E2
mutants carrying individual alanine substitutions of conserved residues between aa 412 and 621 ( Figure 3a) . D03 binding was reduced by more than 50% by substitutions at residues N415, G523 and T526, in line with an epitope overlapping with the CD81 binding site (Figure 3 ).
D03 inhibits HCV cell-to-cell transmission.
We and others have reported that cell-to-cell spread of HCV is resistant to several broadly neutralizing anti-E2 antibodies targeting the CD81 binding site, limiting their potential therapeutic capacity (14-16). The mechanism utilized by HCV for cell-to-cell spread is unknown, and as such antibody resistance is not fully understood. We investigated the ability of D03 to limit cell-to-cell virus transmission using a recently described single-cycle infectious co-culture assay (22) . D03 neutralized more than 95% of the extracellular virus and inhibited cell-to-cell transmitted events (Figure 4 ).
HCV cell-to-cell transmission may be susceptible to the relatively small nanobody (MW ~ 15kD), but not to full IgG molecules (MW ~ 150kD). This would be in line with reports that the small molecules epigallocatechin-3-gallate (29) and El-1 (30) inhibit cell-to-cell transmission. Alternatively, neutralizing activity of D03 on cell-to-cell spread could be attributed to a specific binding mode of the nanobody to the novel epitope described above.
We expressed recombinant antibody fragments of the broadly neutralizing human antibody A8 (24) in Drosophila S2 cells (31, 32) . A8 binds to an epitope defined by contact residues G523, W529, G530 and D535 (24) Characterisation of the selected nanobodies revealed that D03 recognises a novel conserved E2 epitope. This nanobody can inhibit cell-free virus and cell-to-cell transmission, that was previously reported to be resistant to broadly neutralizing antibodies and patient polyclonal Ig (14) .
To maximise the likelihood of inducing cross-reactive nanobodies we immunized with a truncated form of E2 (35) lacking HVR1 -the main target for strain-specific neutralizing epitopes (reviewed in (28)). Crucially we assessed neutralisation breadth using HCVcc and also HCVpp supplemented with E1E2 that are resistant to antibody neutralisation (23).
Epitope mapping showed possible contact residues recognised by D03 included N415, G523 and T526. N415 forms part of the epitope by broadly neutralizing mAbs AP33 and HCV1 (36, 37) . G523 has been identified as contact residue for conformation sensitive antibodies AR3A, 1:7, A8, CBH-5 and to a lesser extent also HC-1 and HC-11 ((38), reviewed in (28)), all of which interact with at least one additional residue among W529, G530 and D535. While D03 also interacts with G523, it does not depend on W529, G530 or D535 as contact residues. Instead, T526 acts as additional contact, a conserved residue that had not been implicated in a neutralizing epitope before. These data suggest that the epitope recognized by D03 overlaps with epitopes utilized by CD81 binding site-specific broadly neutralizing human antibodies, but clearly possesses a novel pattern of contact residues.
Structural analysis of D03 revealed clustering of somatic mutations at the tip of D03
suggesting that the interaction between nanobody and HCV E2 occurs likely in close proximity to CDR1 and CDR2. This indicates that the additional disulfide bridge between the framework upstream of CDR2 and the CDR3 serves to restrict the latter in a conformation that allows maximal accessibility of the tip region of the nanobody. Both neutralizing nanobodies (D03 and C09) possessed this additional disulfide bridge ( Figure   S1c ), whereas both non-neutralizing nanobodies lacked this linkage. It is therefore tempting to speculate that the spatial restriction of the CDR3 contributes to a specific binding mode of the neutralizing nanobodies. Of note, it has been shown that binding of E2 to CD81 is modulated by N-linked sugars forming a glycan shield (39) , which is likely in close proximity of the epitope recognized by D03. This glycan shield could interfere with binding of conventional antibodies, but allow interaction with the tip of heavy-chain antibodies, the diameter of which is smaller due to the absence of light chain. However, structural analysis of D03 in complex with its antigen is required to understand the particularities of this binding mode.
This study is the first description of a nanobody that neutralizes both cell-free virus and cell-to-cell transmission of HCV, which was previously reported to be resistant to patient polyclonal Ig and broadly neutralizing antibodies targeting the CD81 binding site (14) . As such, this entry inhibitor has a potentially unique application to limit HCV spread in the chronically infected liver and represents a significant advance towards therapeutic administration of antibodies to prevent 'neutralization resistant' infection of hepatocytes.
The inhibitory effect of D03 on HCV cell-to-cell transmission demonstrates that the E2 glycoprotein at the surface of transmitted virions is exposed to extracellular antibodies. This suggests that the virus may be transmitting in protected pockets between cells, rather than directly forming synaptic or cellular contacts as observed for HIV-1 (40) , as the latter are likely inaccessible to all extracellular antibodies.
While several nanobodies have entered clinical trials in the last few years (20) , to our knowledge this study provides the first evidence that nanobodies can prevent both cell-free and direct cell-to-cell transmission of a virus, highlighting their potential to be clinically useful entry inhibitors. Nanobodies were incubated at 10µgmL-1 with each HCVpp preparation before adding to Huh7 cells. D03 possessed the greatest cross-neutralizing activity. Neutralization by C09 was limited to genotype 2-derived pseudoparticles. B11 and D04 had no effect on entry of Significant neutralization by D03 was observed at 100 μg/ml, as determined by a one-way ANOVA with Bonferroni correction. **** p<0.0001.
